Back to Peptide Blend Protocols
Peptide BlendGrowth Hormone & Performance10 mg blend2–3× dailySubcutaneousGH Secretagogue
CJC-1295 (No DAC) + Ipamorelin (10 mg Blend) Dosage Protocol
A growth-hormone secretagogue blend with dosing schedules. One of the most widely researched GH-stimulating combinations.
Vial Size
10 mg
Route
Subcutaneous
Frequency
2–3× daily (pulsatile)
Dose Range
100–200 mcg each per injection
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–2 (starter) | 100 mcg each (200 mcg total) |
| Weeks 3+ (maintenance) | 100–200 mcg each (200–400 mcg total) |
Route: Subcutaneous · Frequency: 2–3× daily (pulsatile) · Cycle: 8–12 weeks
How It Works
CJC-1295 (No DAC) stimulates GHRH receptors while Ipamorelin stimulates ghrelin receptors, creating a synergistic double-stimulation of GH release that produces larger and more sustained GH pulses than either peptide alone.
Potential Benefits
- •Synergistic GH stimulation via dual receptor activation.
- •Larger GH pulses than either peptide alone.
- •Minimal cortisol or prolactin elevation.
- •Supports lean body composition and recovery.
Side Effects & Risks
- •Mild water retention.
- •Transient headache or flushing.
- •Prohibited by WADA.
Important Notes
- Administer on an empty stomach for optimal GH pulse.
- Best administered before bed.
- WADA prohibits both peptides in competitive sports.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 14–21 days.
References
- [1]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998.View Source
- [2]Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.